Cell cycle regulators and human hepatocarcinogenesis

Hepato-Gastroenterology

Volumn 45, Issue 23, 1998, Pages 1635-1642

  Hui, Ai Min ^a   Makuuchi, Masatoshi ^a   Li, Xin ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Carcinogenesis; Cell cycle; Hepatocellular carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; GENE MUTATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; G1 PHASE; HUMANS; LIVER NEOPLASMS;

EID: 0031736586     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428.
2. Murakami Y, Hayashi K, Hirohashi S, Sekiya T: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 5520-5525.
3. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992; 52: 6358-6364.
4. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
5. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Dev 1995; 9: 1149-1163.
6. Pardee AB: G1 events and regulation of cell proliferation. Science 1989; 246:603-608.
7. Sherr CJL: Cancer cell cycles. Science 1996; 274: 1672-1677.
8. DelSal G, Loda M, Pagano M: Cell cycle and cancer: critical events at the G1 restriction point. Critical Reviews in Oncogenesis 1996; 7: 127-142.
9. Peter M, Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994; 79: 181-184.
10. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 1994; 79:547-550.
11. Hunter T: Braking the cycle. Cell 1993; 75: 839-841.
12. Sherr CJ: G1 phase progression: Cycling on cue. Cell 1994; 79: 551-555.
13. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707.
14. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockent E, Day III RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-440.
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
16. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR: p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res 1994; 54:5547-5551.
17. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDK2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
18. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995; 11: 2145-2149.
19. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995; 55: 1436-1440.
20. Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck III CH, Busch C, Shamaa M, Elbaz M, Nichols PW, Gonzalgo ML, Malmstrom P-U, Jones PA: High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst 1995; 87:1383-1392.
21. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Issacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 1995; 11: 210-212.
22. Hussussian CJ, Ptruewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark Jr WH, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
23. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-3397.
24. Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55:2756-2760.
25. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994; 27-32.
26. Naumann M, Satalia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W: Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996; 110: 1215-1224.
27. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1: 686-692.
28. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-2530.
29. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Tornout JMV, Jones PA: Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535.
30. INK4 in hepatocellular carcinoma. Hepatology 1996; 24:575-579.
31. Kovar H, Jug G, Aryee DNT, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H: Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15: 2225-2232.
32. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu D-B, Leggett B: Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997; 25: 593-597.
33. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 19: 805-816.
34. Xiong Y, Hannon GJ, Zhang H, Casso D, Koboyashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
35. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulator subunit. Nature 1993; 366: 707-710.
36. Ei-Deiry WS, Kokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
37. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
38. Zhang H, Hannon GJ, Beach D: p21-containing cyclin kinases exist in both active and inactive states. Genes & Dev 1994; 8: 1750-1758.
39. Waga S, Hannon GJ, Beach D, Stillman B: The p21 cyclin-dependent kinase inhibitor directly controls DNA replication via interaction with PCNA. Nature 1994; 369: 574-578.
40. Yang Z-Y, Perkins ND, Ohno T, Nabel EG, Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenecity in vivo. Nature Med 1995; 1: 1052-1056.
41. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR: Tumor suppression by p21WAF1. Cancer Res 1995; 55: 4536-4539.
42. WAF1 mutations in a variety of human malignancies. Blood 1994; 11: 3781-3784.
43. Li Y-J, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R: Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 1995; 10: 599-601.
44. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 1995; 72:1230-1233.
45. WAF1/CIP1 coding region in human tumor cell lines. Mol Carcinog 1996; 16: 221-228.
46. WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54:3391-3395.
47. (WAF1/CIP1) during differentiation. Oncogene 1994; 9:3389-3396.
48. Jiang H, Lin J, Su Z-Z, Collart FC, Huberman E, Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9:3397-3406.
49. 21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 1996; 56: 31-35.
50. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA dependent DNA replication and repair. Nature 1994; 371: 534-537.
51. WAF1/CIP1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
52. WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-579.
53. (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1995; 1: 907-912.
54. Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR, Berchuck AL: Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996; 2: 1571-1575.
55. Vidai MJ, Loganzo Jr F, de Oliverira AR, Hayward NK, Albino AP: Mutations and defective expression of the WAF1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res 1995; 5: 243-250.
56. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH: p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
57. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
58. Kip1, a cyclin-Cdk inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
59. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
60. Kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997; 3:227-230.
61. Kip1 by the viral E1A oncoprotein in TGF-A-treated cells. Nature 1996; 380: 262-265.
62. Kip1 by the human papillomavirus 16E7 oncoprotein. Oncogene 1996; 13: 2323-2330.
63. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-720.
64. Kip1. Cell 1996; 85:721-732.
65. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995; 55:1206-1210.
66. Ponce-Castaneda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Shinfeld J, Massague J, Cordon-Cardo C: p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55: 1211-1214.
67. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266-2269.
68. Stegmaier K, Takeuchi S, Golub TR, Bohhlander SK, Bartram CR, Koeffler HP, Gilliland DG: Mutational analysis of the candidate tumor suppressor gene s TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 1996; 56:1413-1417.
69. Kip1S in primary breast carcinomas. Hum Genet 1996; 9: 91-94.
70. Kip1 expression in hepatocellular carcinomas. Cancer Lett 1998; in press.
71. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997; 3: 231-234.
72. Hui A-M, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Hirohashi S: Cyclin-dependent kinase inhibitors and hepatocarcinogenesis, in: Recent advances in gastroenterological carcinogenesis, Editors: E Tahara, K Sugimachi, T Oohara, Monduzzi Editore, Bologna, 1996; pp 481-485.
73. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold AA: A novel cyclin encoded by a bcll-linked candidate oncogene. Nature 1991; 350: 512-515.
74. Withers D, Harvey R, Faust J, Melnyk O, Carey K, Meeker T: Characteration of a candidate bcl-1 gene. Mol Cell Biol 1991; 11:4846-4853.
75. Xiong Y, Connolly T, Futcher B, Beach D: Human D-type cyclin. Cell 1991; 65: 691-199.
76. Inaba T, Matsushige H, Valentine M, Roussel MF, Sherr CJ, Look AT: Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 1992; 13: 565-574.
77. Xiong Y, Menninger J, Beach D, Ward DC: Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics 1992; 13: 575-584.
78. Jiang W, Kahn SM, Tomita N, Zhang Y-J, Lu S-H, Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 3980-3983.
79. Bartkova J, Lukas J, Muller H, Lutzoft D, Struss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57: 353-361.
80. Alle KM, Henshall SM, Field AS, Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998; 4: 847-854.
81. Zhang Y-J, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein B: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Comm 1993; 196: 1010-1016.
82. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Fukukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga T, Ishizaki K: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-3110.
83. He J, Allen JR, Collins VP, Allalunis-Tuurner MJ, Godbout R, Day RS, James CD: CDK4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines. Cancer Res 1994; 54; 5804-5807.
84. Barkova J, Lukas J, Gulderg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D/cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-5483.
85. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997; 3: 222-225.
86. Yao J, Pollock RE, Lang A, Tan M, Pisters PWT, Goodrich D, El-Naggar A, Yu D: Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res 1998; 4: 1065-1070.
87. INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91:11045-11049.
88. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 3375-3378.
89. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56: 3415-3420.
90. Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu S-X, Benedict WF, Sekiya T: Deletions of chromosome 13q, mutation in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994; 54: 4177-4182.